Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions (probiotics)

January 4, 2026 updated by: Zhujiang Hospital

Effects of DL-endopeptidase Produced by Probiotics on Human Intestinal NOD2 Ligands and Related Functions

We have discovered a type of probiotic that can target activating intestinal NOD2, which is related to a series of human health issues.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This trial requires the subjects to take probiotics for a certain period of time, and we will collect blood, stool and questionnaires for subsequent testing, efficacy evaluation and safety evaluation.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangzhou
      • Guangzhou, Guangzhou, China, 020
        • Industrial Avenue 253, canton

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Tend to participate the trial
  • Willing to provide written informed consent

Exclusion Criteria:

  • Recent use of probiotics, antibiotics, laxatives, or gastrointestinal ulcer medications within the past month.
  • Gastrointestinal symptoms (e.g., constipation, abdominal pain, diarrhea, melena, hematochezia) in the past month.
  • Other conditions considered by researchers for exclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
resistant dextrin
Other: Oral administration
Take it directly
Experimental: probiotics
lactobacillus
Other: Oral administration
Take it directly

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
safty
Time Frame: up to 2 weeks
Adverse reaction by questionnaire survey
up to 2 weeks
NOD2 activation level
Time Frame: up to 2 weeks
the level of NOD2 activation by fecal in vitro experiments
up to 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intestinal barrier
Time Frame: up to 2 weeks
Intestinal Barrier markers
up to 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhujiang Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 5, 2024

Primary Completion (Actual)

June 25, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

October 14, 2024

First Submitted That Met QC Criteria

November 28, 2024

First Posted (Actual)

December 4, 2024

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 4, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZhujiangHZD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

For personal privacy security

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Probiotic Intervention

Clinical Trials on Oral administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe